Losmapimod (GW856553X) 585543-15-3
Product Description
.cp_wz table {border-top: 1px solid #ccc;border-left:1px solid #ccc; } .cp_wz table td{border-right: 1px solid #ccc; border-bottom: 1px solid #ccc; padding: 5px 0px 0px 5px;} .cp_wz table th {border-right: 1px solid #ccc;border-bottom: 1px solid #ccc; padding: 5px 0px 0px 5px;}
Molecular Weight:
383.46 Losmapimod (GW856553X) is a selective, potent, and orally active p38 MAPK Inhibitor with pKi of 8.1 and 7.6 for p38α and p38β, respectively. Phase 3.
Biological Activity
Protocol(Only for Reference)
Kinase Assay: [1]
Animal Study: [1]
Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)
For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.
Chemical Information
Molarity Calculator
Dilution Calculator
Molecular Weight Calculator
Contact us if you need more details on 585543-15-3. We are ready to answer your questions on packaging, logistics, certification or any other aspects about Losmapimod 585543-15-3、GW856553X 585543-15-3. If these products fail to match your need, please contact us and we would like to provide relevant information.
Molecular Weight:
383.46 Losmapimod (GW856553X) is a selective, potent, and orally active p38 MAPK Inhibitor with pKi of 8.1 and 7.6 for p38α and p38β, respectively. Phase 3.
Biological Activity
Description | Losmapimod (GW856553X) is a selective, potent, and orally active p38 MAPK inhibitor with pKi of 8.1 and 7.6 for p38α and p38β, respectively. Phase 3. | |||||
---|---|---|---|---|---|---|
Targets | p38α [1] | p38β [1] | ||||
IC50 | 8.1(pKi) | 7.6(pKi) | ||||
In vitro | | |||||
In vivo | In spontaneously hypertensive stroke-prone rats (SHR-SP), Losmapimod significantly improves survival, endothelial-dependent and -independent vascular relaxation, and indices of renal function, and subsequently attenuates dyslipidemia, hypertension, cardiac remodeling, plasma renin activity (PRA), aldosterone, and interleukin-1beta (IL-1beta). | |||||
Features | |
Protocol(Only for Reference)
Kinase Assay: [1]
In vitro assay | Inhibition of p38α and p38β are determined by use of a ligand-displacement fluorescence polarization assay. |
---|
Animal Study: [1]
Animal Models | Spontaneously hypertensive stroke-prone rats |
---|---|
Formulation | |
Dosages | ~12 mg/kg |
Administration | p.o. |
Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)
Species | Baboon | Dog | Monkey | Rabbit | Guinea pig | Rat | Hamster | Mouse |
Weight (kg) | 12 | 10 | 3 | 1.8 | 0.4 | 0.15 | 0.08 | 0.02 |
Body Surface Area (m2) | 0.6 | 0.5 | 0.24 | 0.15 | 0.05 | 0.025 | 0.02 | 0.007 |
Km factor | 20 | 20 | 12 | 12 | 8 | 6 | 5 | 3 |
Animal A (mg/kg) = Animal B (mg/kg) multiplied by | Animal B Km |
Animal A Km |
For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.
Rat dose (mg/kg) = mouse dose (22.4 mg/kg) × | mouse Km(3) | = 11.2 mg/kg |
rat Km(6) |
Chemical Information
Molecular Weight (MW) | 383.46 |
---|---|
Formula | C22 H26 F N3 O2 |
CAS No. | 585543-15-3 |
Storage | 3 years -20℃Powder |
---|---|
6 months-80℃in solvent (DMSO, water, etc.) | |
Synonyms | GW856553, GSK-AHAB |
Solubility (25°C) * | In vitro | DMSO | 76 mg/mL (198.19 mM) |
---|---|---|---|
Water | <1 mg/mL ( | ||
Ethanol | 41 mg/mL heating (106.92 mM) | ||
* <1 mg/ml means slightly soluble or insoluble. * Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. |
Chemical Name | 3-Pyridinecarboxamide, 6-[5-[(cyclopropylamino)carbonyl]-3-fluoro-2-methylphenyl]-N-(2,2-dimethylpropyl)- |
---|
Molarity Calculator
Dilution Calculator
Molecular Weight Calculator
Contact us if you need more details on 585543-15-3. We are ready to answer your questions on packaging, logistics, certification or any other aspects about Losmapimod 585543-15-3、GW856553X 585543-15-3. If these products fail to match your need, please contact us and we would like to provide relevant information.
Product Categories : MAPK > p38 MAPK Inhibitor
Other Products
Hot Products
Astragaloside AChlortetracycline HCl 64-72-2Paclitaxel 33069-62-4Dexamethasone Acetate 1177-87-3Dinaciclib (SCH727965) 779353-01-4CHIR-124 405168-58-3Ro3280 1062243-51-9TAME 901-47-3CCG-1423 285986-88-110058-F4 403811-55-2Dabigatran (BIBR 953) 211914-51-1H 89 2HCl 130964-39-5T0901317 293754-55-9Aprepitant 170729-80-3Turofexorate Isopropyl (XL335) 629664-81-9BMS-378806 357263-13-9